國家衛生研究院 NHRI:Item 3990099045/4637
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 912265      在线人数 : 1158
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/4637


    题名: Comparison of the antitumor activity of thalidomide between hepatitis B (HBV)and hepatitis C (HCV)-related hepatocellular carcinoma (HCC)
    作者: Hsu, C;Chen, LT;Lai, MY;Yeh, KH;Lee, PH;Cheng, AL
    贡献者: National Institute of Cancer Research
    摘要: Background: Previous studies suggested that chronic HCV infection may be more angiogenic than chronic HBV infection. In this study we sought to clarify if HCV- and HBV-related HCC may respond differently to thalidomide, an anti-angiogenic agent. Methods: One hundred and twelve patients with unresectable and non-embolizable HCC who had participated in 2 prospective clinical trials using single-agent thalidomide. The starting dose of thalidomide was 200 mg per day, and was gradually escalated in 100-mg steps if no limiting toxicities developed. Patients with positive serum HBV surface antigen (HBsAg) and negative anti-HCV antibody were categorized as HBV-related HCC (B-HCC, n=61), while patients with negative HBsAg and positive anti-HCV were categorized as HCV-related HCC (C-HCC, n=33). Response to thalidomide was defined by either (1) a complete or partial response according to WHO criteria or (2) a more than 50% decrease of serum α-fetoprotein level accompanied by clinically stable or improved condition lasting for more than 8 weeks for patients with elevated α-fetoprotein level. Results: All major clinicopathological features were comparable between the 2 groups except for age (C-HCC, 67.5 ± 7.6 years; B-HCC, 53.6 ± 13.7 years, p< 0.001). Eight patients with B-HCC and 9 patients with C-HCC responded to thalidomide treatment. The total response rate to thalidomide was 13.1% (95% C.I. 4.4 to 21.8%) for B-HCC and 27.3% (95% C.I. 11.2 to 43.3%) for C-HCC (p=0.09). Patients with C-HCC appeared to have better median time to disease progression (14.1 weeks vs. 8.3 weeks, p=0.03) and overall survival (32.6 weeks vs. 21.4 weeks, p=0.08) than patients with B-HCC. In multivariate analysis, staging (CLIP score), performance status and types of viral infection were independent predictors for overall survival (p<0.01), while only types of viral infection was independent predictor for time to disease progression (p=0.027). Conclusions: There is a trend favoring better anti-tumor activity of thalidomide in patients with HCV-related HCC. Whether this result is related to angiogenesis inhibition remains to be determined.
    日期: 2004-07
    關聯: Journal of Clinical Oncology. 2004 Jul;22(14):Abstract number 362S.
    Link to: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=26&abstractID=2718
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000223512401436
    显示于类别:[陳立宗] 會議論文/會議摘要

    文件中的档案:

    没有与此文件相关的档案.



    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈